Skip to main content
Journal cover image

Balancing the risks and benefits of long-term antiplatelet therapies for cardiovascular disease: clinical, research, and regulatory implications.

Publication ,  Journal Article
Alfredsson, J; Roe, MT
Published in: J Am Heart Assoc
March 19, 2015

Duke Scholars

Published In

J Am Heart Assoc

DOI

EISSN

2047-9980

Publication Date

March 19, 2015

Volume

4

Issue

3

Start / End Page

e001897

Location

England

Related Subject Headings

  • Secondary Prevention
  • Receptor, PAR-1
  • Pyridines
  • Platelet Aggregation Inhibitors
  • Peripheral Arterial Disease
  • Myocardial Infarction
  • Male
  • Lactones
  • Humans
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Alfredsson, J., & Roe, M. T. (2015). Balancing the risks and benefits of long-term antiplatelet therapies for cardiovascular disease: clinical, research, and regulatory implications. J Am Heart Assoc, 4(3), e001897. https://doi.org/10.1161/JAHA.115.001897
Alfredsson, Joakim, and Matthew T. Roe. “Balancing the risks and benefits of long-term antiplatelet therapies for cardiovascular disease: clinical, research, and regulatory implications.J Am Heart Assoc 4, no. 3 (March 19, 2015): e001897. https://doi.org/10.1161/JAHA.115.001897.
Alfredsson, Joakim, and Matthew T. Roe. “Balancing the risks and benefits of long-term antiplatelet therapies for cardiovascular disease: clinical, research, and regulatory implications.J Am Heart Assoc, vol. 4, no. 3, Mar. 2015, p. e001897. Pubmed, doi:10.1161/JAHA.115.001897.
Journal cover image

Published In

J Am Heart Assoc

DOI

EISSN

2047-9980

Publication Date

March 19, 2015

Volume

4

Issue

3

Start / End Page

e001897

Location

England

Related Subject Headings

  • Secondary Prevention
  • Receptor, PAR-1
  • Pyridines
  • Platelet Aggregation Inhibitors
  • Peripheral Arterial Disease
  • Myocardial Infarction
  • Male
  • Lactones
  • Humans
  • Female